<SEC-DOCUMENT>0001193125-20-044804.txt : 20200221
<SEC-HEADER>0001193125-20-044804.hdr.sgml : 20200221
<ACCEPTANCE-DATETIME>20200221164632
ACCESSION NUMBER:		0001193125-20-044804
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200221
FILED AS OF DATE:		20200221
DATE AS OF CHANGE:		20200221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		20640730

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d894071d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of February 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-36697</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">177-181</FONT> avenue Pierre Brossolette </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9746;&nbsp;&nbsp;Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February&nbsp;21, 2020.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;21, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ramzi Benamar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Ramzi Benamar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g894071001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy
in Children </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (Euronext: DBV&#151;ISIN: FR0010417345&#151;Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today
announced that the U.S. Food and Drug Administration (FDA) has announced an Allergenic Products Advisory Committee meeting to be held on May&nbsp;15, 2020 to discuss the Biologics License Application (BLA) for Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> Peanut. Viaskin Peanut, which is based on&nbsp;epicutaneous immunotherapy (EPIT), is an investigational drug currently under review by the FDA as a treatment for peanut allergy in children.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, nearly one million children suffer from a peanut allergy. For most peanut-allergic children, the burden is lifelong, and about 80% of
them will not have outgrown it by the age of 4 years. Fear of life-threatening reactions triggered by everyday activities may lead to significantly increased anxiety and decreased quality of life for patients and their families. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;There remains a significant unmet need for children suffering from peanut allergy, a potentially life-threatening condition,&#148; </I><B>Daniel
Tass&eacute;</B><I>, </I>Chief Executive Officer of DBV Technologies stated.<I> &#147;We welcome the opportunity to present data for the first and only epicutaneous immunotherapy and remain steadfast in our commitment to offer this important new
treatment option to patients and their families in the second half of 2020, if approved.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company announced on October&nbsp;4, 2019, that
the FDA had accepted the Viaskin Peanut BLA for filing with a target action date of August&nbsp;5, 2020. Viaskin Peanut received Breakthrough and Fast Track Designation from the FDA in 2015 and 2012, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is developing
Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin. With this new class of <FONT STYLE="white-space:nowrap">non-invasive</FONT> product
candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV&#146;s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is
also pursuing a human <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform
in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company&#146;s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company&#146;s ADSs (each representing <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share) are traded on the Nasdaq Global
Select Market (Ticker: DBVT). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g894071002.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may contain forward-looking statements and estimates, including statements regarding the potential of the EPIT platform and Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Peanut as a treatment for peanut-allergic children, the timing of the Advisory Committee meeting, and the Company&#146;s regulatory plans regarding Viaskin Peanut. These forward-looking
statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results
to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and the risk that historical clinical results in one
patient population may not be predictive of future clinical trial results in different patient populations. Furthermore, the timing of any action by the FDA and possible regulatory paths forward cannot be guaranteed, in that, for example, the FDA
may miss its own required deadlines (including the target action date assigned under the Prescription Drug <FONT STYLE="white-space:nowrap">User-Fee</FONT> Act or the date set for the Advisory Committee meeting). A further list and description of
these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in
the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press
Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Investor Relations Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sara Blum
Sherman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations&nbsp;&amp; Strategy </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;212-271-0740</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">sara.sherman@dbv-technologies.com</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joe Becker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Global Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;646-650-3912</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">joseph.becker@dbv-technologies.com</FONT> </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g894071001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g894071001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M+L*+(=QDAQ&32DD%Q_\ A0(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ I@,E_U1I2&A] @I@% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 R7_ %34I%(?02%,
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?VAAOY@_LO%?R,/^$6UK_GR/_?Q?\:/[0PW\P?V7BOY&'_"+:U_SY'_OXO\
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M8\D2.>7</L=M_P ^\?\ WR*?)$.>7</L=M_S[Q_]\BCDB'/+N'V.V_Y]X_\
MOD4<D0YY=P^QVW_/O'_WR*.2(<\NX?8[;_GWC_[Y%')$.>7</L=M_P ^\?\
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M\?\ WR*.2(<\NX?8[;_GWC_[Y%')$.>7</L=M_S[Q_\ ?(HY(ASR[A]CMO\
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MCDB'/+N'V.V_Y]X_^^11R1#GEW$-E;?\^\?_ 'R*.2(^>7<L51 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % "=*5P,Z[UBVMI#"FZ>?_GE&,FK4&R;V*O\ :.LO
MS'I( _VY!FJY8K=A=BKK%Y <WVFR11CK(AW ?E0X1Z,.8U+:[@O(O,MY5D3U
M!J&FAIHFI#%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * ,?4;R>6Z73[%@)FYE?_GFO^-5&*2NR6];%?S(-+?[)IUM]IO/XSW'N
MQJE[VY+T)UM=9F&Z2^C@/]R.,-C\32]U#5QDLVK6 S-&E[;_ ,15=K ?2J2B
M]@=T1&%!%_:>B$9_CB PK^HQV-)/6S"RM=&Q9W:7MI'/'T8=/0]Q425F5%W1
M9I#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 )0 4 4]6R-)NR.HB;^5..Z$]C$O,#P]I0_A\R/-:+XF9O8Z<<5BC46F 4
M 8_B,XL8<?>\],?6KB1(;+QXKM\=?LYS^='V07Q&S6>Q84 %/80M PH * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4@"F 4 % !0 4 % !0 4 % !0 4 % !0 4
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MI[&1'M(G3^&O&6B>+(Y6TF[\UH<>9&ZE'7Z@U$H..Y2::T-^HN,*8!0 4 %
M!0 4GH!SOBGQII/@];5M5,P%R6$?E1[ONXSGTZBKC!RV)<DCGHOC3X/D8*UQ
M=1@_Q-;G _+-5[*2$IQ9W5C?6VHVD=W9SI/;RC<DD9R"*AIK<LLT@,'Q;XEB
M\)>'Y=7G@>>.)T0HA )W$#J?K3C&[L*3Y5<L^'-:3Q%H%GJT4+0I<IO",<D<
MD?THDN5V"+NKFK2&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % ",H88(!'H: MT.8O=$O=,NGO] *JSG,ULY^1_IZ
M&NB-127+,X*E&=-\]'YH@BU;0M4N-EPSZ?J X96_=L#]>AING./F@ABZ4G9Z
M/^O4U5LM2"_Z-JVZ/L70,?SK)N*^)'4KO5,K7L$%O&7UG6'*#G8&V _@.33C
M>6D41.I&"O49GQZG=:K']D\,6XM[8'#W<BX _P!T=S6O)&'O5'J<KK3K^[1T
M\SH-)T>VTBVV1#=(W,DK\LY]2:PG-S.JC1C17GW-.H.@* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H RO$_\ R*>L
M_P#7E-_Z :J/Q(4MF>3_  CE\,Q^%+H:T^F";[4Q479CW;=J_P![G'6MZJDI
M*QE#EMJ4O#DEE/\ ',2>$PJZ7M/FB%=L94)\V!Z;L?C1)/D][<4=):%/2_$?
MC_7O%.J:)H^KMN+R8:4@")%?&0<<=0.A/TJN6G&/-(2<VVCH/$OB[Q/;:MIO
M@S3]0M[74$MHQ>7TS@9?9DX9N@QSG&3G%1&$7[Q;DUH4+CQ5XF\ :E9RWWB2
MV\0:7,^)0DBNZ\<X'48ZCG%-04UHA<S3+'C+QMJ]YXZ;0;77DT'3HT4BY92-
MY*ALD@9[X'0=<T1IVC=H)2;>AT&@2>)-#T?6=6O/$T'B"PMK1I;<0L'+. 3R
M0,C@>O>LW9Z6+C='$:)X@\3>,#-=/X_MM)NP^V*T<^6K=Q[8_,UM)0CHT91<
MF>V^&H=4@T"SCUF[2[OPG[V6/&UN>,8 SQCG%<TK7T-XW2/,/C]CRO#^>F^;
M_P!DK:AU,JG0U/%VI?#O_A%+R-FTJ6X>%EA6V53)YFWY<;>1SBE%3<@?+8Y?
MP9XLN/!OPBN[\KYC2WS16(;E=Q49)_V00353CSST"+<8CH;OQO=:+_PD)\<V
M<5UL\Y; S(,IC."O0$CMBBT4[6"\K%K7_%<WB[X&W%]=JBWD=U'#,$&%+!U.
M0/0@BB,>6HA.5XDC^-I_!WP<\."P*#4;M66,NNX*H8EFQW/( ^M"I\\V^B*3
MM'0S[^_\:^'M*&O_ /";V5[,,--9"5)-H..B]#C/.,>U-1@W:Q-Y6.ROM9\2
M>+/!6E:MX6U"VT]I<B\:?"B,C@D$@X 8'\"*R48QDU(MW<=#A;_Q1XO\!:C9
MS77B>VUJTG;+I%()1@$;@<\KP>"*U2A)62,W*479FY\0_'.KQ>)M/T;3=572
M+&YMXY7NG7D;\\DX)  &.,<U%.G%1;94I.^AM>#(=?MM0DOKKQM;ZUHD<#2.
M(V#N&[9ZD#J>O:IERM62''FW9RMOXL\2>/=9O_L'B:WT'2K=_P!UO98V8'.W
MW8X&3S@5HX1@E="3DWH;_P /O&>L/XNNO"FO7\.H21(3;W4."'QR?F'!R#GU
M&,&E4IKEYDAQD[V9ZO7.:A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!%/-';6\D\SA(HU+NQZ* ,DT"V,R4:+J^E#4)%MKFR:,R"?
M*[,9R#Z5<92B[(SG2IS6J,BQ\,>&M8LTOM-G>2UDSL>"8E3@X./Q%;+$U(Z-
M'(\#2EJF_P"OD:5KX1T:T<.MH)&'>4[_ -#Q42KU)&E/!TH:[^IM)$D:A44*
MHZ # %8MWW.M*VB'8]Z-ABT@"F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MT:P5D<S\<=,OM2BT,65E<7.QY=_DQ%]H.SK@<5=)I7)J)LH>./A%9V>@+?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MV,O-G[GVACA1]1C/X&A>Y#U%\4K'HR\5D:"T % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % ",<*2.PI/1#6YS&@Z]/_9ES)JDH>2*/SU; &Z,Y]/0@
MC\JZJU-*W(O+YG!AZTG?VC[OY7:?W6%TK6[R.SG.H!I[MKKR8H4 !R5#;>W
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M]!ZUT3CRP34>BU.*E-RJM.?5JVG^1IVVL3W6GB\CTR4(^TQAI$&X$=3SP/\
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MO[J=TO\ @^1MU@=84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M"0Q;^]NZY]\TKA8OP6\5K!'!!&L<48"JJC  % R2@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
&* "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g894071002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g894071002.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@!#2 !WIK8H6@EA0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (:06 =Z:V*%H)
M84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M %($(U P%"=B7<6BXPHNAA1= %%T 470!1= %%T 470!1= %%T 470!1= %%
MT 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470
M!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %
M%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 47
M0!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1=
M%%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 470!1= %%T 4
M70!1= %%T 470!1= %%T 470!1= %%T 470!1<!&HN!]'?\ "GM)'\</_@,/
M\:\%T*S_ .7C/>6,I+_ET@_X4]I7]^'_ ,!A_C1]7K?\_&'URE_SZ0?\*>TK
M^_#_ . P_P :7U>M_P _&/Z[2_Y](/\ A3VE?WX?_ 8?XT?5ZW_/QA]=I?\
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M]7K?\_&'UVE_SZ0?\*>TK^_#_P" P_QH^KUO^?C#Z[2_Y](/^%/:5_?A_P#
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %*P"$@#)( I@5GU"RB.'
MNX5/H7%/E;%=(?%=VTW$4\;_ .ZP-%FMPNF3TAA0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M((R#6>VAIT'4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 (3B@##BQJ.JW%S<8-K9G;&#TW#J?TK36*LNI&[&VUL^MRF[O"39Y_<0@
MXR/4^M)M05EN"U-N.**)=L<:HOHHQ47N5HB"ZT^UO(BDT2GT8<$?0TXRML)Q
MN9ELSPW3:1?'SXW4F)VYW#T/O5/NA+LR;1Y&MY9],E;+P'*$]T/2E/5<P+1\
MIL5)84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!!=R>
M5:32?W4)_2G'=">QS^\P>$$Q]^?C_OH_X5K]LC[)T5O$(8(XAT10OY5DS1;$
MM( H Q_$7[JUM[H?>@F5OP[U<"9#9%V>*;:0'B6!E_+FJ_Y=M$_:-JLC0* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MVPWFXYQCRW']*T=&:W1A'%49;2_,TK>\@NE)A?< <'@BLVFMS:,XRV)Z184
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M:1"*WB2*->BH,"N=MO5GH**BK)$V.:10M !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 '2@"KJ$SV^F7<T9P\<+LI]" 336KL)['.^$]9OM4^'%KJ]W,'O9+
M9Y&D"@98%L' X["G)6E82>ER/X9Z[J'B+P1:ZEJ<PFNGDD5G"!<@,0.!Q3G'
MEE8(NZ.PS4%!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MY7?'%*;+3LCA(QG<1[G(Y]S1/W5RCAJ[GI8K(T%H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M:5C7I#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MEVWG6YA65-X4_P!]"AX..AP11L,FI % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@!/\: %H .] "4 '2@ % !0 'J*3 0#
M &.*8 IR* %[T  Z4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
C0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
